Handelen Genprex, Inc. - GNPX CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Handelsvoorwaarden
| Spread | 0.0355 | ||||||||
|
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.024068% | ||||||||
|
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.001846% | ||||||||
| Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
| Min. verhandelde hoeveelheid | 1 | ||||||||
| Valuta | USD | ||||||||
| Marge | 20% | ||||||||
| Effectenbeurs | United States of America | ||||||||
| Handelscommissie | 0% |
*Information provided by Capital.com
Belangrijkste statistieken
| Prev. Close* | 0.7522 |
| Open* | 0.7732 |
| 1-Jaarlijkse Verandering* | -67.38% |
| Dagelijks bereik* | 0.7274 - 0.7732 |
| 52 wekelijks bereik | 0.75-2.67 |
| Weekgemiddelde volume (10 dagen) | 386.52K |
| Gemiddeld volume (3 maanden) | 8.56M |
| Marktkapitalisatie | 40.27M |
| P/E Ratio | -100.00K |
| Uitstaande Aandelen | 51.97M |
| Omzet | N/A |
| EPS | -0.47 |
| Dividend (opbrengst %) | N/A |
| Beta | -0.31 |
| Volgende inkomsten datum | N/A |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
|---|---|---|---|---|---|---|
| Mar 20, 2023 | 0.7274 | -0.0656 | -8.27% | 0.7930 | 0.7931 | 0.7210 |
| Mar 17, 2023 | 0.7449 | -0.0700 | -8.59% | 0.8149 | 0.8149 | 0.7283 |
| Mar 16, 2023 | 0.7870 | -0.0179 | -2.22% | 0.8049 | 0.8091 | 0.7558 |
| Mar 15, 2023 | 0.7945 | -0.0751 | -8.64% | 0.8696 | 0.8781 | 0.7677 |
| Mar 14, 2023 | 0.8400 | -0.1078 | -11.37% | 0.9478 | 0.9541 | 0.8400 |
| Mar 13, 2023 | 0.8952 | 0.0272 | 3.13% | 0.8680 | 0.9172 | 0.8505 |
| Mar 10, 2023 | 0.8868 | -0.1109 | -11.12% | 0.9977 | 1.0077 | 0.8779 |
| Mar 9, 2023 | 0.9977 | -0.0299 | -2.91% | 1.0276 | 1.0376 | 0.9937 |
| Mar 8, 2023 | 1.0276 | -0.0699 | -6.37% | 1.0975 | 1.0975 | 1.0077 |
| Mar 7, 2023 | 1.0276 | -0.0699 | -6.37% | 1.0975 | 1.1075 | 1.0176 |
| Mar 6, 2023 | 1.0875 | -0.0200 | -1.81% | 1.1075 | 1.1175 | 1.0875 |
| Mar 3, 2023 | 1.1175 | -0.0299 | -2.61% | 1.1474 | 1.1574 | 1.0875 |
| Mar 2, 2023 | 1.1274 | -0.0100 | -0.88% | 1.1374 | 1.1574 | 1.0576 |
| Mar 1, 2023 | 1.1274 | -0.1197 | -9.60% | 1.2471 | 1.2671 | 1.1174 |
| Feb 28, 2023 | 1.2671 | 0.1597 | 14.42% | 1.1074 | 1.3370 | 1.1074 |
| Feb 27, 2023 | 1.1174 | -0.1098 | -8.95% | 1.2272 | 1.2272 | 1.0975 |
| Feb 24, 2023 | 1.3170 | 0.0000 | 0.00% | 1.3170 | 1.3769 | 1.2970 |
| Feb 23, 2023 | 1.3669 | -0.3992 | -22.60% | 1.7661 | 1.8659 | 1.2871 |
| Feb 22, 2023 | 1.6363 | -0.0200 | -1.21% | 1.6563 | 1.6762 | 1.6064 |
| Feb 21, 2023 | 1.6663 | 0.0300 | 1.83% | 1.6363 | 1.7062 | 1.6363 |
Genprex, Inc. Events
| Tijd (UTC) (UTC) | Land | Evenement |
|---|---|---|
| No events scheduled | ||
- Jaarlijks
- Per kwartaal
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Totale inkomsten | 0 | 0 | 0 | 0 | 0 | 0 |
| Inkomsten | 0 | 0 | 0 | 0 | 0 | 0 |
| Totale bedrijfskosten | 4.13216 | 3.31235 | 12.3635 | 10.6827 | 17.9616 | 19.6008 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 3.77641 | 3.01917 | 11.3862 | 8.7026 | 10.6359 | 10.9705 |
| Onderzoek & Ontwikkeling | 0.35488 | 0.28993 | 0.97143 | 1.96701 | 7.30292 | 8.60775 |
| Depreciation / Amortization | 0.00086 | 0.00324 | 0.00589 | 0.01307 | 0.02278 | 0.02253 |
| Bedrijfsresultaat | -4.13216 | -3.31235 | -12.3635 | -10.6827 | -17.9616 | -19.6008 |
| Netto inkomen voor belastingen | -4.13216 | -3.31416 | -12.3723 | -10.6548 | -17.9428 | -19.5956 |
| Netto inkomen na belastingen | -4.13216 | -3.31416 | -12.3723 | -10.6548 | -17.9428 | -19.5956 |
| Netto inkomen voor extra. Posten | -4.13216 | -3.31416 | -12.3723 | -10.6548 | -17.9428 | -19.5956 |
| Netto inkomen | -4.13216 | -3.31416 | -12.3723 | -10.6548 | -17.9428 | -19.5956 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -4.13216 | -3.31416 | -12.3723 | -10.6548 | -17.9428 | -19.5956 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -4.13216 | -3.31416 | -12.3723 | -10.6548 | -17.9428 | -19.5956 |
| Verwateringsaanpassing | 0 | |||||
| Verwaterd Netto Inkomen | -4.13216 | -3.31416 | -12.3723 | -10.6548 | -17.9428 | -19.5956 |
| Verwaterd Gewogen Gemiddelde Aandelen | 16.1882 | 13.035 | 13.771 | 16.027 | 35.5229 | 47.0973 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.25526 | -0.25425 | -0.89843 | -0.6648 | -0.5051 | -0.41607 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||||
| Verwaterde Genormaliseerde Winst per Aandeel | -0.25526 | -0.25425 | -0.89843 | -0.6648 | -0.5051 | -0.41607 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | -0.00181 | -0.0088 | 0.02791 | 0.01881 | 0.00513 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Totale inkomsten | 0 | 0 | 0 | 0 | 0 |
| Inkomsten | 0 | 0 | 0 | 0 | 0 |
| Totale bedrijfskosten | 6.4917 | 3.98722 | 3.43893 | 5.68292 | 5.72336 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 4.31631 | 2.4581 | 2.00044 | 2.19563 | 3.8558 |
| Onderzoek & Ontwikkeling | 2.16914 | 1.52628 | 1.432 | 3.48033 | 1.86084 |
| Depreciation / Amortization | 0.00624 | 0.00285 | 0.00649 | 0.00696 | 0.00673 |
| Bedrijfsresultaat | -6.4917 | -3.98722 | -3.43893 | -5.68292 | -5.72336 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | 0.00198 | 0.0011 | 0.00106 | 0.00099 | 0.00088 |
| Netto inkomen voor belastingen | -6.48971 | -3.98612 | -3.43787 | -5.68193 | -5.72248 |
| Netto inkomen na belastingen | -6.48971 | -3.98612 | -3.43787 | -5.68193 | -5.72248 |
| Netto inkomen voor extra. Posten | -6.48971 | -3.98612 | -3.43787 | -5.68193 | -5.72248 |
| Netto inkomen | -6.48971 | -3.98612 | -3.43787 | -5.68193 | -5.72248 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -6.48971 | -3.98612 | -3.43787 | -5.68193 | -5.72248 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -6.48971 | -3.98612 | -3.43787 | -5.68193 | -5.72248 |
| Verwaterd Netto Inkomen | -6.48971 | -3.98612 | -3.43787 | -5.68193 | -5.72248 |
| Verwaterd Gewogen Gemiddelde Aandelen | 45.5461 | 47.3725 | 47.6124 | 47.8353 | 47.8796 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.14249 | -0.08414 | -0.07221 | -0.11878 | -0.11952 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Verwaterde Genormaliseerde Winst per Aandeel | -0.14249 | -0.08414 | -0.07221 | -0.11878 | -0.11952 |
- Jaarlijks
- Per kwartaal
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Totaal vlottende activa | 1.63883 | 0.19357 | 8.84707 | 2.97664 | 27.7044 | 39.1402 |
| Geldmiddelen en kortetermijnbeleggingen | 1.6023 | 0.16125 | 8.60092 | 2.00249 | 27.3197 | 38.6289 |
| Cash | 1.6023 | 0.16125 | 8.60092 | 2.00249 | 27.3197 | 38.6289 |
| Prepaid Expenses | 0.03653 | 0.02348 | 0.23685 | 0.17172 | 0.38455 | 0.51135 |
| Total Assets | 1.91053 | 1.25954 | 9.26896 | 3.53423 | 31.3672 | 42.8623 |
| Property/Plant/Equipment, Total - Net | 0.00516 | 0.0078 | 0.02435 | 0.04465 | 0.03944 | 0.04861 |
| Intangibles, Net | 0.24104 | 0.29857 | 0.37945 | 0.4912 | 3.61267 | 3.66476 |
| Other Long Term Assets, Total | 0.02551 | 0.75959 | 0.01809 | 0.02173 | 0.01074 | 0.00869 |
| Total Current Liabilities | 0.28566 | 0.83096 | 0.38782 | 0.51068 | 0.45072 | 1.5853 |
| Accounts Payable | 0.28566 | 0.62907 | 0.29507 | 0.43626 | 0.19297 | 0.9732 |
| Notes Payable/Short Term Debt | 0 | 0.20189 | 0.09275 | 0.07443 | 0 | 0 |
| Total Liabilities | 0.28566 | 0.83096 | 0.38782 | 0.51068 | 0.45072 | 1.5853 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.62487 | 0.42857 | 8.88114 | 3.02355 | 30.9165 | 41.277 |
| Preferred Stock - Non Redeemable, Net | 0.00137 | |||||
| Common Stock | 0.00033 | 0.01172 | 0.01524 | 0.01926 | 0.04312 | 0.04787 |
| Additional Paid-In Capital | 15.7614 | 17.8692 | 38.6906 | 43.4837 | 89.2956 | 119.247 |
| Retained Earnings (Accumulated Deficit) | -14.1382 | -17.4524 | -29.8247 | -40.4795 | -58.4222 | -78.0179 |
| Total Liabilities & Shareholders’ Equity | 1.91053 | 1.25954 | 9.26896 | 3.53423 | 31.3672 | 42.8623 |
| Total Common Shares Outstanding | 16.1882 | 13.035 | 15.2392 | 19.2638 | 43.1177 | 47.8747 |
| Totale Vorderingen, Netto | 0.00884 | 0.0093 | 0.00066 | 0.00013 | 0 | |
| Accounts Receivable - Trade, Net | 0.00884 | 0.0093 | 0.00066 | 0.00013 | 0 | |
| Total Inventory | 0.80178 | |||||
| Other Current Liabilities, Total | 0.25776 | 0.6121 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 50.3777 | 48.0615 | 45.6447 | 39.1402 | 35.7031 |
| Geldmiddelen en kortetermijnbeleggingen | 47.0687 | 44.2435 | 42.0205 | 38.6289 | 34.5553 |
| Cash | 47.0687 | 44.2435 | 42.0205 | 38.6289 | 34.5553 |
| Totale Vorderingen, Netto | 0.00013 | 0.00013 | 0.00013 | 0 | 0.03217 |
| Accounts Receivable - Trade, Net | 0.00013 | 0.00013 | 0.00013 | 0 | 0.03217 |
| Total Inventory | 3.1079 | 3.06236 | 2.87505 | ||
| Prepaid Expenses | 0.201 | 0.7556 | 0.74903 | 0.51135 | 1.1156 |
| Total Assets | 51.0365 | 48.7314 | 46.3272 | 42.8623 | 39.4094 |
| Property/Plant/Equipment, Total - Net | 0.0373 | 0.03949 | 0.04434 | 0.04861 | 0.04188 |
| Intangibles, Net | 0.6107 | 0.61967 | 0.62736 | 3.66476 | 3.65444 |
| Other Long Term Assets, Total | 0.01074 | 0.01074 | 0.01074 | 0.00869 | 0.01 |
| Total Current Liabilities | 0.61363 | 1.04722 | 1.16189 | 1.5853 | 2.38482 |
| Accounts Payable | 0.33897 | 0.36979 | 0.59194 | 0.9732 | 1.25298 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.27466 | 0.67743 | 0.56995 | 0.6121 | 1.13184 |
| Total Liabilities | 0.61363 | 1.04722 | 1.16189 | 1.5853 | 2.38482 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 50.4229 | 47.6842 | 45.1653 | 41.277 | 37.0246 |
| Common Stock | 0.04732 | 0.04752 | 0.0478 | 0.04787 | 0.04788 |
| Additional Paid-In Capital | 115.287 | 116.535 | 117.453 | 119.247 | 120.717 |
| Retained Earnings (Accumulated Deficit) | -64.9119 | -68.8981 | -72.3359 | -78.0179 | -83.7403 |
| Total Liabilities & Shareholders’ Equity | 51.0365 | 48.7314 | 46.3272 | 42.8623 | 39.4094 |
| Total Common Shares Outstanding | 47.3148 | 47.5229 | 47.8036 | 47.8747 | 47.8797 |
| Other Equity, Total | 0 |
- Jaarlijks
- Per kwartaal
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Netto-inkomen/Beginsaldo | -4.13216 | -3.31416 | -12.3723 | -10.6548 | -17.9428 | -19.5956 |
| Geldmiddelen uit Operationele Activiteiten | -1.24826 | -2.17159 | -6.84653 | -6.91872 | -13.9351 | -14.2849 |
| Geldmiddelen uit Operationele Activiteiten | 0.00086 | 0.00324 | 0.00589 | 0.01307 | 0.02278 | 0.02253 |
| Niet-Geldelijke Posten | 2.65742 | 1.32389 | 5.43538 | 3.52998 | 4.24619 | 4.27821 |
| Veranderingen in het Operationeel Kapitaal | 0.22562 | -0.18457 | 0.08454 | 0.19299 | -0.26128 | 1.00995 |
| Geldmiddelen uit Investeringsactiviteiten | -0.08953 | -0.06342 | -0.10332 | -0.9469 | -2.33725 | -0.0838 |
| Kapitaaluitgaven | -0.08953 | -0.06342 | -0.10332 | -0.14512 | -0.12799 | -0.07244 |
| Geldmiddelen uit Financieringsactiviteiten | 2.70587 | 0.79397 | 15.3895 | 1.26719 | 41.5895 | 25.6779 |
| Uitgifte (Aflossing) van aandelen, netto | 2.70587 | 0.79397 | 15.3895 | 1.26719 | 41.5895 | 25.6779 |
| Nettowijziging in Geldmiddelen | 1.36808 | -1.44104 | 8.43967 | -6.59843 | 25.3172 | 11.3092 |
| Overige Cash Flow investeringsposten, Totaal | -0.80178 | -2.20926 | -0.01136 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -6.48971 | -10.4758 | -13.9137 | -19.5956 | -5.72248 |
| Cash From Operating Activities | -5.46528 | -8.43209 | -11.0668 | -14.2849 | -4.08386 |
| Cash From Operating Activities | 0.00624 | 0.00909 | 0.01558 | 0.02253 | 0.00673 |
| Non-Cash Items | 0.67174 | 1.8092 | 2.48457 | 4.27821 | 1.47011 |
| Cash Taxes Paid | 0 | 0 | |||
| Cash Interest Paid | 0 | 0 | |||
| Changes in Working Capital | 0.34645 | 0.22545 | 0.34669 | 1.00995 | 0.16179 |
| Cash From Investing Activities | -0.11003 | -0.07851 | 0.08978 | -0.0838 | 0.01032 |
| Capital Expenditures | -0.10077 | -0.02719 | -0.04622 | -0.07244 | -0.00184 |
| Other Investing Cash Flow Items, Total | -0.00926 | -0.05132 | 0.136 | -0.01136 | 0.01216 |
| Cash From Financing Activities | 25.3243 | 25.4344 | 25.6779 | 25.6779 | 0 |
| Issuance (Retirement) of Stock, Net | 25.3243 | 25.4344 | 25.6779 | 25.6779 | 0 |
| Net Change in Cash | 19.749 | 16.9238 | 14.7008 | 11.3092 | -4.07354 |
| Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
|---|---|---|---|---|---|---|
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.5144 | 1826600 | 1043 | 2022-12-31 | LOW |
| Varner (John Rodney) | Individual Investor | 2.2348 | 1161535 | 625000 | 2023-02-18 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.069 | 555623 | 2408 | 2022-12-31 | LOW |
| Confer (Ryan M.) | Individual Investor | 0.8379 | 435499 | 245000 | 2023-02-18 | MED |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.8314 | 432137 | -8520 | 2022-12-31 | LOW |
| Berger (Mark Stanley) | Individual Investor | 0.4714 | 245000 | 245000 | 2023-02-18 | |
| Vaczy (Catherine M) | Individual Investor | 0.4714 | 245000 | 245000 | 2023-02-18 | |
| Kumar (Hermant) | Individual Investor | 0.3848 | 200000 | 200000 | 2023-02-18 | |
| UBS Financial Services, Inc. | Investment Advisor | 0.3089 | 160546 | -119788 | 2022-12-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.2496 | 129739 | 0 | 2022-12-31 | LOW |
| Cypress Capital, LLC | Investment Advisor | 0.1924 | 100000 | 0 | 2022-12-31 | MED |
| Verus Capital Partners, LLC | Investment Advisor | 0.1703 | 88500 | -2000 | 2022-12-31 | MED |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.1663 | 86430 | 11029 | 2022-12-31 | LOW |
| Group One Trading, L.P. | Research Firm | 0.1161 | 60354 | -79668 | 2022-12-31 | HIGH |
| Silvercrest Asset Management Group LLC | Investment Advisor/Hedge Fund | 0.1077 | 56000 | 0 | 2022-12-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.1056 | 54900 | -18656 | 2022-12-31 | HIGH |
| IHT Wealth Management, LLC | Investment Advisor | 0.1008 | 52375 | 0 | 2022-12-31 | LOW |
| Staley Capital Advisers, Inc. | Hedge Fund | 0.0962 | 50000 | 0 | 2022-12-31 | LOW |
| Citadel Advisors LLC | Hedge Fund | 0.0687 | 35688 | 21508 | 2022-12-31 | HIGH |
| StoneX Group Inc. | Research Firm | 0.0676 | 35150 | 0 | 2022-12-31 | HIGH |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group 500000+
Handelaren
92000+
Actieve klanten per maand
$53000000+
Maandelijks beleggingsvolume
$30000000+
Probeer het nu Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
Handelscommissie
0
- 1:1
Hefboom
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Positiegrootte (hefboomwerking x investering):
Openingskoers
Slotkoers
Short Long
Genprex, Inc. Company profile
Over Genprex, Inc.
Genprex, Inc. is een gentherapiebedrijf in klinische ontwikkeling dat zich toelegt op de ontwikkeling van behandelingen voor kanker en diabetes. Het voornaamste kandidaat-geneesmiddel voor kanker van de Vennootschap, REQORSA Immunogene therapie (ook GPX-001 genoemd), wordt ontwikkeld voor de behandeling van niet-kleincellige longkanker (NSCLC). Het actieve bestanddeel in REQORSA is een plasmide dat het TUSC2-gen tot expressie brengt en dat is ingekapseld in een DOTAP-cholesterol nanodeeltje. TUSC2 is een tumoronderdrukkend gen dat zowel tumordodende (via apoptose) als immunomodulerende effecten heeft. De Vennootschap gebruikt haar ONCOPREX Nanoparticle Delivery System om het plasmide dat het TUSC2-gen tot expressie brengt in kankercellen af te leveren. Zijn gentherapie voor diabetes, ook GPX-002 genoemd, is ontworpen om alfacellen in de pancreas om te vormen tot functionele bèta-achtige cellen, die insuline kunnen produceren maar voldoende verschillen van bètacellen om het immuunsysteem van het lichaam te omzeilen.
| Industry: | Bio Therapeutic Drugs |
Suite 3.322
1601 Trinity Street, Bldg. B
78712
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 500.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen